10mg · lyophilized · single vial
4.6(880 researcher reviews)Dual GLP-1 / GIP receptor agonist.
For research and educational use only. Not for human consumption. Consult a licensed provider before use.
Tirzepatide is a once-weekly dual agonist of GIP and GLP-1 receptors. The SURMOUNT trial program showed up to ~22.5% mean body-weight reduction at the 15 mg dose — the current benchmark among approved weight-management agents.
Every KINETYX vial is filled in a controlled cleanroom and sealed with tamper-evident packaging. Batch documentation includes identity confirmation, HPLC purity analysis and concentration verification.
Curated from public preclinical literature. All content is educational.
Tirzepatide is a synthetic peptide that simultaneously activates two incretin receptors — GLP-1 and GIP. This dual-agonist mechanism produces stronger effects on glucose control and body-weight than single-receptor GLP-1 agonists like semaglutide.
It is dosed once-weekly and titrated over months. The SURMOUNT trials reported ~22.5% mean body-weight reduction at the 15 mg dose, currently the leading approved weight-management agent by efficacy.
• GLP-1 receptors: enhance insulin secretion, slow gastric emptying, suppress glucagon, and reduce appetite.
• GIP receptors: amplify insulin response, improve peripheral insulin sensitivity, and support lipid metabolism.
Together, they produce compounded appetite regulation and glycemic control that exceeds mono-agonist GLP-1s in head-to-head studies.
• Up to ~22.5% mean weight reduction in trials (15 mg)
• Superior HbA1c reduction vs. GLP-1 mono-agonists
• Improved lipid and inflammation markers
• Once-weekly dosing with predictable titration
Weekly subcutaneous titration: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, stepping up every 4 weeks.
1 vial = 10 mg. At the 5 mg weekly step, a vial covers ~2 weeks.
Nausea (titration-dependent)
Diarrhea or constipation
Decreased appetite
Injection-site reaction
For in-vitro research use only. Not for human or veterinary consumption.
Enter the bacteriostatic water volume you'll add and the target dose. We'll compute the units on a standard U-100 insulin syringe.
Reference only. Assumes U-100 syringe (100 units = 1 mL). Not medical advice.
Weekly subcutaneous titration: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, stepping up every 4 weeks.
1 vial = 10 mg. At the 5 mg weekly step, a vial covers ~2 weeks.
Refrigerate reconstituted vial at 2–8°C. Use within 30 days. Lyophilized vials stable ≥12 months at −20°C.
Yes. Every batch of Tirzepatide ships with an HPLC purity report and identity confirmation from an independent lab. Batch numbers are searchable in our Lab Results portal.
Ambient, insulated mailer, discreet plain packaging. Includes BAC water + 12 syringes. Domestic delivery in 24–48h.
Currently US only for research supply. International researcher accounts require verification.
Lyophilized vials remain stable for 12+ months at −20°C. Once reconstituted, refrigerate at 2–8°C and use within 30 days.
Orders placed by 2pm ET ship same day.
Overnight or 2-day, tracked, ambient shipping.
Orders over $150 ship free within the US.
Unopened vials returnable within 14 days. Batch-verified refunds always honored.
Been running a conservative research protocol for four weeks. Response curve is consistent with published literature.
Compared this side by side with two other suppliers. KINETYX was the only one that documented concentration verification.
Been running a conservative research protocol for four weeks. Response curve is consistent with published literature.
Compared this side by side with two other suppliers. KINETYX was the only one that documented concentration verification.